Abstract 1657P
Background
Pancreatic ductal adenocarcinoma (PDAC) represents the fourth highest rate of cancer-related deaths worldwide. The absence of early symptoms, early metastasis, and inefficient systemic therapies lead to a fatal prognosis for PDAC patients. Currently, surgical resection is the only curative option. However, it is often linked to severe postoperative complications and a considerable tumor recurrence rate. Therefore, identifying the resistance mechanisms of PDAC and developing targeted therapies is crucial.
Methods
Mutant KRAS and its effector Pdk1 play a major role in PDAC carcinogenesis. Previous works showed that Pdk1 deletion causes impairment of PDAC cell proliferation in vitro and in vivo. However, a minor subpopulation of cells continues to proliferate. To investigate this resistance, a genome wide CRISPR/Cas9 knockout screen was performed. Members of SAGA and Mediator complexes were among the top hits of the screen. The CRISPR knockouts of these genes were generated in the bulk PDAC epithelial cell line and in two single cell clones - one resistant and one sensitive to Pdk1 deletion. Clonogenic assays were performed to analyze the proliferation of the knocked-out cells, while RNA sequencing was conducted to investigate the differentially expressed genes.
Results
In the CRISPR/Cas9 knockout screen, members of SAGA and Mediator complexes showed enrichment in Pdk1 deletion resistant clones. Amongst all hits, significant proliferation of the Usp22- and Atxn7L3- as well as Med13- and Med16-knockout in the Pdk1 deleted PDAC cells was observed, with the strongest effect in the resistant clone. Several enhanced or downregulated hallmark pathways were observed in the knocked-out cells, providing insight into possible resistance mechanisms of the PDAC.
Conclusions
The results of the RNA sequencing of both SAGA and Mediator knocked-out cells showed an enhancement of the Hedgehog signalling, a pathway reported in the initiation of a growing number of cancers. The results of this research suggest furthermore, that the loss of the connecting units Atxn7L3 and Med16 promotes an unhinged transcription activity of the enzymatically active SAGA and Mediator complexes and leads to an enhanced PDAC cell proliferation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
German Research Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1677P - Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma
Presenter: Daniele Lavacchi
Session: Poster session 22
1678P - A retrospective real-world study of nimotuzumab combined with chemotherapy for first-line treatment of advanced pancreatic cancer: A single center propensity score matched analysis
Presenter: Yinying Wu
Session: Poster session 22
1679P - Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis
Presenter: Luca Mastrantoni
Session: Poster session 22
1680P - Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure
Presenter: Amol Gupta
Session: Poster session 22
1681P - A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer
Presenter: Siyi Zou
Session: Poster session 22
1682P - Impact of metastatic site on survival in patients with synchronous metastatic pancreatic adenocarcinoma (PDAC): A national prospective BACAP study
Presenter: Emily Alouani
Session: Poster session 22
1683TiP - Trial in progress: NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer-NEO-IMPACT
Presenter: Sarah Maloney
Session: Poster session 22
1684TiP - PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
Presenter: Philippe Cassier
Session: Poster session 22
1685TiP - Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): A multicenter randomized controlled trial
Presenter: Jacob van Dam
Session: Poster session 22
1686TiP - Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations
Presenter: Teresa Macarulla
Session: Poster session 22